Lymphotec, Inc. operates a medical laboratory. The company was founded on April 26, 1999 and is headquartered in Tokyo, Japan.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Galpharma targets research and development of sugar chain-binding proteins focus on galectin 9. It provides information on functional analysis of the protein in each disease and substance that involves sugar chain-binding proteins to the pharmaceutical companies. It is founded in 2000 in Kagawa, Japan.

Immune Control, Inc. was formed in 2001 based on technology developed in the laboratories of Professors Bradford Jameson and Ana Tretiakova, Department of Biochemistry, Drexel University College of Medicine. Initial funding came from Argil Management, LLC, of Boston. In 2003, Stephen Roth, Ph.D., became president and CEO of Immune Control. The Company plans to complete an investigational new drug (IND) application to be submitted to the Food and Drug Agency in 2005. The IND application will propose the use of an already marketed serotonin antagonist in multiple myeloma patients in a small, and relatively short, phase 1/2 clinical trial. If the drug has significant, clinical efficacy against the malignant B cells characteristic of multiple myeloma, they would immediately begin plans for a larger, phase 3 trial. Positive results in the first trial would constitute clinical proof-of-concept for the Company's basic premise-that serotonin antagonists have clinical utility against inappropriately activated immune cells. Another Company goal focuses on proprietary serotonin antagonists that are more potent than those already approved, and that do not cross the blood-brain barrier, making them free of adverse neurological side-effects. Such new chemical entities would be screened for their abilities to bind to specific immunological serotonin receptors, which are now being characterized. The Company has made progress with at least two receptors, one of which has apparently not previously been described. Research on the molecular biology of the receptors is underway at Drexel University College of Medicine, and new chemical entities to be screened for serotonin antagonist activity are being synthesized for the Company. Ultimately, they hope to find compounds that can be used against many hematologic cancers, transplant rejection, and against a host of diseases that are all caused by inappropriate lymphocyte activation. Examples of such diseases are type I diabetes, rheumatoid arthritis, lupus, asthma, and many of the muscular dystrophies. The market size for drugs that treat each of these conditions exceeds a billion dollars. Simultaneously, the Company aggressively protects its intellectual property with patent applications. Novel use applications, novel compound applications, and novel receptor applications are all examples of the Company's existing IP portfolio, which has been licensed exclusively and worldwide to the Company by Drexel University.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Toyo Seikan Group Holdings Ltd. manages its group companies, which are involved in the manufacture and sale of packaging containers and equipment for packaging systems. It operates through the following segments: Packaging Business, Steel Plate-related Business, Functional Materials-related Business, Real Estate-related Business, and Other Businesses. The Packaging Business segment manufactures and markets containers and general filling products. The Steel Plate-related Business segment includes steel plate materials for cans, electronic components, and industry machinery parts. The Functional Materials-related Business segment sells aluminum substrates for magnetic disks, functional films for optics, pigments, and gel coats. The Real Estate-related Business segment leases office buildings and commercial facilities. The Other Businesses segment includes automobile press dies, hard alloys, and non-life insurance agency business. The company was founded on June 25, 1917 and is headquartered in Tokyo, Japan.

Formed in 1985, the University of Maryland Biotechnology Institute (UMBI) is part of the University System of Maryland. It was created to provide a unified focus for Maryland's biotechnology research and education.

UK Research & Innovation (doing business as United Kingdom Research & Innovation) is a private company headquartered in London, UK. The firm provides science and technology research services.\nThe company says this about itself: Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.

BINEX Co., Ltd. engages in the manufacture and sale of pharmaceuticals. It operates through the following business divisions: Bio, Pharmaceutical Manufacturing and Sales, and others. The Bio division provides bio pharmaceutical consignment production and bio analysis services. The Pharmaceutical Manufacturing and Sales division offers medicines for digesting, anti-inflammatory analagesic drug, probiotics, collyrium, antibiotics, urinary system disease, circulation disease, external ointment, antitussive expectorants, and others. The Others division provides processing services. The company was founded on December 17, 1957 and is headquartered in Busan, South Korea.

ENZYCHEM LIFESCIENCES Corp. engages in developing, manufacturing, and distributing pharmaceutical products. Its main products include beta lactam antibiotics, non-beta lactam active pharmaceutical ingredient (APIs), and others. The beta lactam antibiotics include Cefazedone, Cefbuperazone and Ceftizoxime. The non-beta lactam APIs include D-cycloserine and Talniflumate. The company was founded on July 20, 1999 and is headquartered in Jecheon-si, South Korea.

Martin Pharmaceuticals is a developer of a treatment of Acute-on-Chronic Liver Failure (ACLF). The company drug shifts the generation of energy in the liver from fatty acid oxidation to glucose oxidation so that fewer of these toxic molecules are produced. As a consequence, there is less damage to individual hepatocytes, leading to less hepatocyte death.

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

Part of Kirin Holdings Co., Ltd., Kyowa Engineering Co. Ltd. is a company headquartered in Japan. The firm provides civil engineering services.

Celltech Co., Ltd. is engaged in producing and developing healthcare and biopharmaceutical products. Its main products include anticancer cell therapy which is named by NKM(Natural Killer Mix cell) Injection, GMP(Good Manufacturing Practice) system and medical devices. The company was founded on August 20, 1986 and is headquartered in Sungnam, South Korea.